Ranibizumab Plus Indomethacin

• Status: Completed
• Trial end date: 2017-07-25

Summary

To evaluate whether indomethacin eyedrops plus intravitreal ranibizumab (IVR) provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization (CNV) in age-related macular degeneration.

• Phase: Phase 4

Details

• Lead Sponsor: Università degli Studi di Brescia
• Treatments: Indomethacin; Ranibizumab